APAC, MENA, and Africa Sickle Cell Anemia Market
完整報告名稱與涵蓋範圍
APAC, MENA, and Africa Sickle Cell Anemia Market Research Report Information By Treatment (Pharmacotherapy, Blood Transfusion, Bone Marrow Transplant, and Gene Therapy), by End User (Hospitals, Specialty Clinics, and Others), by Region Forecast to 2032
報告摘要
APAC, MENA, and Africa Sickle Cell Anemia Market Research Report Information By Treatment (Pharmacotherapy, Blood Transfusion, Bone Marrow Transplant, and Gene Therapy), by End User (Hospitals, Specialty Clinics, and Others), by Region Forecast to 2032
Market Overview
APAC, MENA, and Africa Sickle Cell Anemia Market is anticipated to register a notable CAGR of 14.77% during the review period. Sickle Cell Anemia is a genetic disorder that primarily affects red blood cells. It is caused by a mutation in the HBB gene, leading to the production of abnormal hemoglobin, called hemoglobin S. This causes red blood cells to become rigid and sickle-shaped, which can obstruct blood flow and cause various health complications.
The growing government support and policies associated with sickle cell anemia, and increased prevalence of sickle cell anemia increases the demand for drug treatment are major factors driving the growth of the APAC, MENA, and Africa. However, the high cost of bone marrow transplants and the side effects associated with drug treatment are expected to restrain the growth of the market. Nevertheless, the government is forming partnerships with manufacturers to produce affordable sickle cell disease medications and advancements in treatment options, which is attributed to creating lucrative opportunities for the players operating in the APAC, MENA, and Africa market.
Market Segmentation
Based on end user, the APAC, MENA, and Africa sickle cell anemia market is segmented into hospitals, specialty clinics, and others. The hospitals segment dominated the market in 2022, while the specialty clinics segment is projected to be the fastest-growing segment during the forecast period, 2023–2032.
Based on treatment, the APAC, MENA, and Africa Sickle Cell Anemia market has been segmented into pharmacotherapy, blood transfusion, bone marrow transplant, and gene therapy. The blood transfusion segment dominated the market in 2022, while the gene therapy segment is projected to be the fastest-growing segment during the forecast period, 2023–2032.
Based on region, the APAC, MENA, and Africa sickle cell anemia market has been segmented into Asia-Pacific, Middle East & North Africa, Africa. Asia-Pacific accounted for the largest market share in 2022 and is anticipated to reach USD 4,220.86 million by 2032, registering a CAGR of 16.31% during the forecast period. However, Asia-Pacific is projected to grow at the highest CAGR of 16.31% during the forecast period.
Major Players
The key players operating in the APAC, MENA, and Africa Sickle Cell Anemia market are Pfizer Inc, Cipla ltd., Novartis AG, Emmaus Medical, Inc, Zydus Group, Vertex Pharmaceuticals Incorporated, and Nestlé.
授權報價
| Single User Price | $2,950 USD |
| Multi User Licence (up to 10 users) | $3,950 USD |
| Enterprisewide Price (Global Site License) | $5,250 USD |
目錄 Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 16
2 MARKET INTRODUCTION 18
2.1 DEFINITION 18
2.2 SCOPE OF THE STUDY 18
2.3 RESEARCH OBJECTIVE 18
2.4 MARKET STRUCTURE 18
3 RESEARCH METHODOLOGY 19
3.1 OVERVIEW 19
3.2 DATA FLOW 22
3.2.1 DATA MINING PROCESS 22
3.3 PURCHASED DATABASE: 23
3.4 SECONDARY SOURCES: 24
3.4.1 SECONDARY RESEARCH DATA FLOW: 25
3.5 PRIMARY RESEARCH: 26
3.5.1 PRIMARY RESEARCH DATA FLOW: 27
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED 28
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: 29
3.6.1 REVENUE ANALYSIS APPROACH 29
3.7 DATA FORECASTING 30
3.7.1 DATA FORECASTING TECHNIQUE 30
3.8 DATA MODELING 31
3.8.1 MICROECONOMIC FACTOR ANALYSIS: 31
3.8.2 DATA MODELING: 32
3.9 TEAMS AND ANALYST CONTRIBUTION 33
4 MARKET DYNAMICS 35
4.1 INTRODUCTION 35
4.2 DRIVERS 36
4.2.1 GROWING GOVERNMENT SUPPORT AND POLICIES ASSOCIATED WITH SICKLE CELL ANAEMIA 36
4.2.2 INCREASED PREVALENCE OF SICKLE CELL ANEMIA INCREASES THE DEMAND FOR DRUG TREATMENT 36
4.3 RESTRAINTS 37
4.3.1 HIGH COST OF BONE MARROW TRANSPLANT AND SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT 37
4.4 OPPORTUNITY 38
4.4.1 GOVERNMENT IS FORMING PARTNERSHIPS WITH MANUFACTURERS TO PRODUCE AFFORDABLE SICKLE CELL DISEASE MEDICATIONS 38
4.4.2 ADVANCEMENTS IN TREATMENT OPTIONS 39
5 MARKET FACTOR ANALYSIS 40
5.1 PORTER'S FIVE FORCES MODEL 40
5.1.1 THREAT OF NEW ENTRANTS 40
5.1.2 BARGAINING POWER OF SUPPLIERS 41
5.1.3 THREAT OF SUBSTITUTES 41
5.1.4 BARGAINING POWER OF BUYERS 41
5.1.5 INTENSITY OF RIVALRY 41
5.2 IMPACT OF COVID-19 ON THE APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET 42
5.3 GLOBAL REVENUE OF MAJOR BRANDS 42
6 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET, BY TREATMENT 43
6.1 INTRODUCTION 43
6.2 PHARMACOTHERAPY 45
6.3 BLOOD TRANSFUSION 45
6.4 BONE MARROW TRANSPLANT 45
6.5 GENE THERAPY 46
7 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET, BY END USER 47
7.1 INTRODUCTION 47
7.2 HOSPITALS 49
7.3 SPECIALTY CLINICS 49
7.4 OTHERS 49
8 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET, BY REGION 50
8.1 OVERVIEW 50
8.2 ASIA-PACIFIC 51
8.2.1 CHINA 53
8.2.2 INDIA 54
8.2.3 JAPAN 55
8.2.4 AUSTRALIA 55
8.2.5 SOUTH KOREA 56
8.2.6 REST OF ASIA-PACIFIC 57
8.3 MIDDLE EAST & NORTH AFRICA 58
8.3.1 UAE 61
8.3.2 EGYPT 61
8.3.3 SAUDI ARABIA 62
8.3.4 KUWAIT 63
8.3.5 QATAR 63
8.3.6 OMAN 64
8.3.7 IRAN 65
8.3.8 JORDAN 65
8.3.9 REST OF MENA 66
8.4 AFRICA 67
8.4.1 SOUTH AFRICA 69
8.4.2 ETHIOPIA 70
8.4.3 NIGERIA 70
8.4.4 REST OF AFRICA 71
9 COMPETITIVE LANDSCAPE 73
9.1 INTRODUCTION 73
9.2 MARKET SHARE ANALYSIS, 2022 73
9.3 COMPETITOR DASHBOARD 74
9.4 PUBLIC PLAYERS STOCK SUMMARY 75
9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 75
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 76
9.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL 76
9.6.2 AGREEMENT 76
10 COMPANY PROFILES 77
10.1 PFIZER INC 77
10.1.1 COMPANY OVERVIEW 77
10.1.2 FINANCIAL OVERVIEW 78
10.1.3 PRODUCTS OFFERED 78
10.1.4 KEY DEVELOPMENTS 79
10.1.5 SWOT ANALYSIS 79
10.1.6 KEY STRATEGIES 80
10.2 EMMAUS MEDICAL, INC 81
10.2.1 COMPANY OVERVIEW 81
10.2.2 FINANCIAL OVERVIEW 82
10.2.3 PRODUCTS OFFERED 82
10.2.4 KEY DEVELOPMENTS 83
10.2.5 SWOT ANALYSIS 83
10.2.6 KEY STRATEGIES 84
10.3 NOVARTIS AG 85
10.3.1 COMPANY OVERVIEW 85
10.3.2 FINANCIAL OVERVIEW 86
10.3.3 PRODUCTS OFFERED 87
10.3.4 KEY DEVELOPMENTS 87
10.3.5 SWOT ANALYSIS 87
10.3.6 KEY STRATEGIES 88
10.4 CIPLA LTD 89
10.4.1 COMPANY OVERVIEW 89
10.4.2 FINANCIAL OVERVIEW 90
10.4.3 PRODUCTS OFFERED 90
10.4.4 KEY DEVELOPMENTS 90
10.4.5 SWOT ANALYSIS 91
10.4.6 KEY STRATEGIES 91
10.5 NESTLÉ 92
10.5.1 COMPANY OVERVIEW 92
10.5.2 FINANCIAL OVERVIEW 93
10.5.3 PRODUCTS OFFERED 93
10.5.4 KEY DEVELOPMENTS 94
10.5.5 KEY STRATEGIES 94
10.6 ZYDUS GROUP 95
10.6.1 COMPANY OVERVIEW 95
10.6.2 FINANCIAL OVERVIEW 96
10.6.3 PRODUCTS OFFERED 96
10.6.4 KEY DEVELOPMENTS 96
10.6.5 SWOT ANALYSIS 97
10.6.6 KEY STRATEGIES 97
10.7 SALIUS PHARMA PVT. LTD. 98
10.7.1 COMPANY OVERVIEW 98
10.7.2 FINANCIAL OVERVIEW 98
10.7.3 PRODUCTS OFFERED 98
10.7.4 KEY DEVELOPMENTS 99
10.7.5 KEY STRATEGIES 99
10.8 VERTEX PHARMACEUTICALS INCORPORATED 100
10.8.1 COMPANY OVERVIEW 100
10.8.2 FINANCIAL OVERVIEW 101
10.8.3 PRODUCTS OFFERED 101
10.8.4 KEY DEVELOPMENTS 101
10.8.5 SWOT ANALYSIS 102
10.8.6 KEY STRATEGIES 102
10.9 TAJ PHARMACEUTICALS LIMITED 103
10.9.1 COMPANY OVERVIEW 103
10.9.2 FINANCIAL OVERVIEW 103
10.9.3 PRODUCTS OFFERED 103
10.9.4 KEY DEVELOPMENTS 104
10.9.5 KEY STRATEGIES 104
10.10 CELON LABS 105
10.10.1 COMPANY OVERVIEW 105
10.10.2 FINANCIAL OVERVIEW 105
10.10.3 PRODUCTS OFFERED 105
10.10.4 KEY DEVELOPMENTS 106
10.10.5 KEY STRATEGIES 106
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 32
TABLE 2 GLOBAL REVENUE OF MAJOR BRANDS 42
TABLE 3 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 44
TABLE 4 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET, FOR PHARMACOTHERAPY, BY REGION, 2019–2032 (USD MILLION) 45
TABLE 5 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET, FOR BLOOD TRANSFUSION, BY REGION, 2019–2032 (USD MILLION) 45
TABLE 6 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET, FOR BONE MARROW TRANSPLANT, BY REGION, 2019–2032 (USD MILLION) 45
TABLE 7 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET, FOR GENE THERAPY, BY REGION, 2019–2032 (USD MILLION) 46
TABLE 8 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 48
TABLE 9 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET, FOR HOSPITALS, BY REGION, 2019–2032 (USD MILLION) 49
TABLE 10 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET, FOR SPECIALTY CLINICS, BY REGION, 2019–2032 (USD MILLION) 49
TABLE 11 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 49
TABLE 12 APAC, MENA, AND AFRICA: SICKLE CELL ANEMIA MARKET, BY REGION, 2019–2032 (USD MILLION) 50
TABLE 13 ASIA-PACIFIC: SICKLE CELL ANEMIA MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 52
TABLE 14 ASIA-PACIFIC: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 53
TABLE 15 ASIA-PACIFIC: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 53
TABLE 16 CHINA: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 53
TABLE 17 CHINA: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 54
TABLE 18 INDIA: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 54
TABLE 19 INDIA: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 54
TABLE 20 JAPAN: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 55
TABLE 21 JAPAN: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 55
TABLE 22 AUSTRALIA: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 55
TABLE 23 AUSTRALIA: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 56
TABLE 24 SOUTH KOREA: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 56
TABLE 25 SOUTH KOREA: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 56
TABLE 26 REST OF ASIA-PACIFIC: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 57
TABLE 27 REST OF ASIA-PACIFIC: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 57
TABLE 28 MENA: SICKLE CELL ANEMIA MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 59
TABLE 29 MENA: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 60
TABLE 30 MENA: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 60
TABLE 31 UAE: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 61
TABLE 32 UAE: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 61
TABLE 33 EGYPT: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 61
TABLE 34 EGYPT: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 62
TABLE 35 SAUDI ARABIA: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 62
TABLE 36 SAUDI ARABIA: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 62
TABLE 37 KUWAIT: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 63
TABLE 38 KUWAIT: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 63
TABLE 39 QATAR: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 63
TABLE 40 QATAR: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 64
TABLE 41 OMAN: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 64
TABLE 42 OMAN: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 64
TABLE 43 IRAN: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 65
TABLE 44 IRAN: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 65
TABLE 45 JORDAN: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 65
TABLE 46 JORDAN: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 66
TABLE 47 REST OF MENA: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 66
TABLE 48 REST OF MENA: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 66
TABLE 49 AFRICA: SICKLE CELL ANEMIA MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 68
TABLE 50 AFRICA: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 68
TABLE 51 AFRICA: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 69
TABLE 52 SOUTH AFRICA: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 69
TABLE 53 SOUTH AFRICA: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 69
TABLE 54 ETHIOPIA: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 70
TABLE 55 ETHIOPIA: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 70
TABLE 56 NIGERIA: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 70
TABLE 57 NIGERIA: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 71
TABLE 58 REST OF AFRICA: SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 71
TABLE 59 REST OF AFRICA: SICKLE CELL ANEMIA MARKET, BY END USER, 2019–2032 (USD MILLION) 71
TABLE 60 PUBLIC PLAYERS STOCK SUMMARY 75
TABLE 61 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 75
TABLE 62 PRODUCT LAUNCH/ PRODUCT APPROVAL 76
TABLE 63 AGREEMENT 76
TABLE 64 PFIZER INC: PRODUCT OFFERED 78
TABLE 65 PFIZER INC: KEY DEVELOPMENTS 79
TABLE 66 EMMAUS MEDICAL, INC: PRODUCT OFFERED 82
TABLE 67 EMMAUS MEDICAL, INC: KEY DEVELOPMENTS 83
TABLE 68 NOVARTIS AG: PRODUCT OFFERED 87
TABLE 69 CIPLA LTD: PRODUCTS OFFERED. 90
TABLE 70 NESTLÉ: PRODUCTS OFFERED 93
TABLE 71 ZYDUS GROUP: PRODUCTS OFFERED 96
TABLE 72 SALIUS PHARMA PVT. LTD.: PRODUCTS OFFERED 98
TABLE 73 VERTEX PHARMACEUTICALS INCORPORATED: PRODUCTS OFFERED 101
TABLE 74 TAJ PHARMACEUTICALS LIMITED: PRODUCTS OFFERED 103
TABLE 75 CELON LABS: PRODCUTS OFFERED 105
LIST OF FIGURES
FIGURE 1 APAC, MENA AND AFRICA SICKLE CELL ANEMIA MARKET: STRUCTURE 18
FIGURE 2 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET REPORT: MARKET GROWTH FACTOR ANALYSIS (2022-2032) 35
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032) 37
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032) 38
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET 40
FIGURE 6 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET; TREATMENT SEGMENT ATTRACTIVENESS, (USD MILLION) 43
FIGURE 7 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET, BY TREATMENT, 2022 & 2032 (USD MILLION) 44
FIGURE 8 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET SHARE, BY TREATMENT, 2022 44
FIGURE 9 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET; END USER SEGMENT ATTRACTIVENESS, (USD MILLION) 47
FIGURE 10 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET, BY END USER, 2022 & 2032 (USD MILLION) 48
FIGURE 11 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET SHARE, BY END USER, 2022 48
FIGURE 12 APAC, MENA, AND AFRICA: SICKLE CELL ANEMIA MARKET, BY REGION, 2022 & 2032 (USD MILLION) 50
FIGURE 13 ASIA-PACIFIC: SICKLE CELL ANEMIA MARKET SHARE (%), BY REGION, 2022 51
FIGURE 14 ASIA-PACIFIC MARKET ANALYSIS: SICKLE CELL ANEMIA MARKET, 2019-2032 (USD MILLION) 51
FIGURE 15 ASIA-PACIFIC: SICKLE CELL ANEMIA MARKET, BY COUNTRY, 2022 & 2032 (USD MILLION) 52
FIGURE 16 ASIA-PACIFIC: SICKLE CELL ANEMIA MARKET SHARE (%), BY COUNTRY, 2022 52
FIGURE 17 MIDDLE EAST & NORTH AFRICA MARKET ANALYSIS: SICKLE CELL ANEMIA MARKET, 2019-2032 (USD MILLION) 58
FIGURE 18 MENA: SICKLE CELL ANEMIA MARKET, BY COUNTRY, 2022 & 2032 (USD MILLION) 59
FIGURE 19 MENA: SICKLE CELL ANEMIA MARKET SHARE (%), BY COUNTRY, 2022 60
FIGURE 20 AFRICA MARKET ANALYSIS: SICKLE CELL ANEMIA MARKET, 2019-2032 (USD MILLION) 67
FIGURE 21 AFRICA: SICKLE CELL ANEMIA MARKET, BY COUNTRY, 2022 & 2032 (USD MILLION) 67
FIGURE 22 AFRICA: SICKLE CELL ANEMIA MARKET SHARE (%), BY COUNTRY, 2022 68
FIGURE 23 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET PLAYERS: COMPETITIVE ANALSIS, 2022 73
FIGURE 24 COMPETITOR DASHBOARD: APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET 74
FIGURE 25 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT 78
FIGURE 26 PFIZER INC: SWOT ANALYSIS 79
FIGURE 27 EMMAUS MEDICAL, INC.: FINANCIAL OVERVIEW SNAPSHOT 82
FIGURE 28 EMMAUS MEDICAL, INC: SWOT ANALYSIS 83
FIGURE 29 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 86
FIGURE 30 NOVARTIS AG.: SWOT ANALYSIS 87
FIGURE 31 CIPLA LTD: FINANCIAL OVERVIEW 90
FIGURE 32 CIPLA LTD: SWOT ANALYSIS 91
FIGURE 33 NESTLÉ.: FINANCIAL OVERVIEW 93
FIGURE 34 ZYDUS GROUP: FINANCIAL OVERVIEW 96
FIGURE 35 ZYDUS GROUP: SWOT ANALYSIS 97
FIGURE 36 VERTEX PHARMACEUTICALS INCORPORATED: FINANCIAL OVERVIEW SNAPSHOT 101
FIGURE 37 VERTEX PHARMACEUTICALS INCORPORATED: SWOT ANALYSIS 102
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們